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Table 1
OA-Related Mean Cumulative One-Year Costs by Joint Location, Age, and
Comorbidity
Subgroup Total
Medical*
Inpatient Outpatient Physical or
Occupational
Therapy
Pharmacy
Overall $8,644 $3,533 $4,921 $265 $2,179
Joint location
Knee $9,466 $4,178 $5,093 $292 $2,086
Hip $12,478 $7,473 $4,818 $295 $2,047
Hand $6,705 $1,505 $5,004 $221 $2,256
Age group, y
18–44 $10,857 $3,398 $7,070 $440 $1,794
45–64 $12,799 $5,400 $7,144 $395 $2,258
65y $3,510 $1,429 $2,002 $84 $2,156
Comorbidity
Hypertension $8,917 $3,855 $4,857 $232 $2,519
CVD $10,844 $4,993 $5,575 $157 $3,150
Diabetes $10,815 $4,709 $5,859 $242 $3,358
CVD ¼ cardiovascular disease; OA ¼ osteoarthritis.
*Total medical costs are equal to the sum of inpatient, outpatient, and emergency
room costs, excluding physical or occupational therapy and pharmacy costs.
yCosts for patients 65 are underestimated because payments observed here are
supplements to Medicare.
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pain for more than one month who were likely to have OA. Outcome
measures were measurements that evaluated physical functioning and
pain. The included articles were assessed for bias and the results were
summarized according to best evidence synthesis.
Results: Of the 9068 studies that were found, 27 articles were included.
In patients with knee OA, the average course of physical functioning
varied between studies (inconsistent evidence). The samewas found for
the average course of knee pain in studies with a follow up period
shorter than three years. Only one study examined the course of pain
over a longer period, and found an improvement in pain over six years
(weak evidence). In addition, in patients with hip OA the average course
of physical functioning in studies with a follow up period shorter than
three years was found to be stable (strong evidence). Because only one
study examined the course of physical functioning over a period longer
than three years, weak evidence was found for a stable course over 5
years. No publications were found that examined the course of pain in
patients with hip OA. With regard to prognostic factors, in patients with
knee OA strong evidence was found for various prognostic factors for
future deterioration in physical functioning i.e. older age, a low to
middle education level, higher body mass index, high morbidity count,
use of pain medication, greater difﬁculties with physical functioning at
baseline, lower knee extension strength, higher pain intensity, patella-
femoral joint compression, lower walking ability, poor mental health
and a low vitality. With regard to predictors for future knee pain, a
longer symptom duration, bilateral knee symptoms and a higher level
of pain at baseline were found to predict future pain in patients with
knee OA (strong evidence). In hip OA strong evidence was found that a
high morbidity count and a low vitality increase the likelihood of
deterioration of physical functioning. No publications were found on
prognostic factors for future pain.
Conclusion: The average course of physical functioning and pain in
patients with knee OAwas found to be variable between studies. In hip
OA, the long-term course of physical functioning was found to be stable.
In comparison to a previous review stronger evidence was found for a
number of variables to be prognostic factors of physical functioning and
pain, including demographic factors, clinical factors, knee character-
istics and psychosocial factors. Knowledge on prognostic factors can be
used to inform patients on the likely course of their condition and to
adapt treatment according to the prognosis. Although many studies
have been carried out recently, more studies with a longitudinal design
are warranted, especially in patients with hip OA.
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Purpose: Osteoarthritis (OA) is the most common form of arthritis and
the leading cause of working age disabilities. Over 27 million US adults
have clinical OA, and different types of burdens exist based on the
disease stages and locations. The burden of OA by joint location, age, or
comorbidity has not been well studied. The objective of this study was
to assess the excess health care resource use and costs attributable to
OA by joint location, age, and comorbidity in a privately insured
population.
Methods: 428,084 OA patients aged18 were selected from a US-based
employer claims database (1999–2011). Controls were selected from the
same database by matching OA patients 1:1 by age, gender, index date,
and follow-up time to patients who never had OA in their claims his-
tories. Descriptive analyses were used to compare baseline character-
istics and study period medical resource use and costs, inﬂated to 2011
US dollars using annual medical Consumer Price Index data (Bureau of
Labor Statistics). Statistical comparisons were made using McNemar’s
test for categorical variables and the Wilcoxon signed-rank test for
continuous variables.
Results: Among all the OA patients studied,181,379 had a primary claim
of knee OA; 48,617 had hip OA; 29,340 had hand OA; and 30,549 had
spine OA. The average age of OA patients was 63 years and 59% were
female. At baseline, OA patients tended to have a greater comorbidity
burden than controls (P< 0.001). The occurrence of the 4most common
comorbidities between the OA group and controls were hypertension
(45% vs 30%, respectively), cardiovascular disease (14% vs 8%,respectively), diabetes (16% vs 10%, respectively), and depression (8% vs
4%, respectively). OA patients aged 18 incurred total annual medical
costs of $8,644 vs $2,273 in controls (P < 0.001). 20% of all OA patients
had at least 1 primary joint arthroplasty, 1% had a revision joint
arthroplasty, and 2% had arthrodesis. The cost per surgery ranged from
$16,000 to $25,000. On average, a hip arthroplasty cost $18,425 and a
knee arthroplasty cost $17,433. Annual pharmacy cost was $2,179 for OA
patients and $1,096 for controls. OA-related health care costs are
summarized by joint locations, age, and comorbidity in Table 1.Con-Conclusions: Patients with OA incur greater medical and pharmacy
costs than those without OA. The burden of OA varies substantially by
joint location. Surgical procedures are the most signiﬁcant cost among
all categories, and therefore is also one of the main drivers of the total
cost. In contrast, pharmacy costs are rather small due to no disease-
modifying OA drug (DMOAD) available. Hand OA had lower costs than
knee and hip OA due to lack of DMOADs and effective surgery. In
summary, OA presents a great disease and economic burden. The cur-
rent treatment options are limited to generic symptom-modifying
drugs and late-stage surgical management of the disease, but the latter
is only available for certain joints.
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Purpose: Osteoarthritis (OA) produces pain and mobility limitations
which require intensive primary care management. Once the disease
reaches an advanced stage, total hip replacements (THRs) are very
effective at improving patients’ health and reducing demand for pri-
mary care resources. The costs of managing OA before surgery, however,
have not been thoroughly explored leading to most assessments of
THRs to exclude these costs from economic models. We aimed to
describe the use of primary care resources attributable to OA in the UK
and to estimate the costs borne by the NHS for these services.
Methods: We used data from the General Practice Research Database
(GPRD, now CPRD) of all patients with a primary THR before 31
December 2006 who were 45 years of age or older at the time of
operation. The data set included the clinical history of up to ﬁve controls
for each THR case. Controls had no record of hip arthroplasty, OA or
arthritis, and were matched to cases by GP practice, gender and age.
Data included consultations with GPs, nurses, consultants and allied
health professionals (AHP) as well as prescription of selected 25 drugs
grouped into categories as NSAIDs, opioid and non-opioid analgesics,
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resource use speciﬁcally attributable to OA by subtracting the mean
number of visits and units of medication by each set of non-OA controls
from the values reported by the respective THR case. Records for up to
15 years before the THR were considered, hence the number of obser-
vations varied by year preceding the operation. For the year immedi-
ately prior to THR, data from 21,572 THR cases (and an equal number of
sets of controls) were used, this number being reduced to 2,079 ﬁfteen
years prior to the operation. Based on these records, we estimated the
number of consultations and prescriptions attributable to OA as well as
their cost to the NHS (in 2011 sterling) based on unit costs reported by
the Personal Social Services Research Unit and the British National
Formulary.
Results: Patients receiving a THR reported an additional 1.8 (95% CI
1.74–1.88) visits to the GP compared to non-OA controls during the year
immediately prior to THR. A statistically signiﬁcant increased use of at
least 0.5 yearly visits was recorded up to ﬁve years before the operation,
whereas for six or more years the increased use was statistically sig-
niﬁcant but lower than 0.5. For nurses, consultants and various AHPs
such as acupuncturists, chiropractors, dieticians and physiotherapists
no statistically signiﬁcant increased use greater than 0.5 visits per year
was found. In terms of burden to the NHS, overall consultation costs
accelerated more rapidly as surgery approached. Costs amounted to an
extra £7 ﬁfteen years before the operation, rising to £11, £18 and £61 at
10, ﬁve and one year before surgery, respectively. In all years, con-
sultations with a GP accounted for 93% to 100% of total consultation
costs. Prescription burden to the NHS for the management of OA was
estimated to be zero at 15 years before a THR, £2.15 at 10 years, £6.75 at
ﬁve and £37 (CI £35.1-£38.1) during the year before THR. For this year,
NSAIDs accounted for 41% of the additional prescription costs, followed
by non-opioids (paracetamol) with 36% and opioids 28%. Laxatives and
ulcer prevention medication were found to be prescribed, in average,
more to non-OA patients than to those receiving a THR. This pattern of
prescriptions was found to change over time as the breakdown for year
10 before surgery was 55% of costs directed at paracetamol, 38% to
NSAIDs and 7% to opioids. Overall costs to the NHS including both
consultation and prescriptions due to OA went from £7 to £13, £25 and
£102 at 15, 10, ﬁve and one year before surgery, respectively (see Fig.).
Whilst consultation costs accounted for all total costs 15 years before
surgery, its proportional weight decreased to 83%, 73% and 64% at 10,
ﬁve and one year prior to the operation.
Conclusions: Overall NHS primary care costs attributable to OA are
estimated at £7 and exclusively due to consultations 15 years before a
THR. As the operation approaches, costs increase up to £102 the year
before surgery, 37% of which due to prescriptions costs. Consultations
with GPs account for almost all of consultation costs and prescriptions
change from milder to stronger analgesics as paracetamol is overtaken
by NSAIDs and a larger share of opioids the more advanced the disease
and the closer patients are to a THR. Based on these results, it would be
worth exploring the effects of THR on resource use as well as a potential
application of the latter as predictor of need for THR.370
THE ROLE OF INCIDENT KNEE INJURY OR KNEE SURGERY AS
PREDICTORS OF SUBSEQUENT RADIOGRAPHIC OSTEOARTHRITIS:
DATA FROM THE OSTEOARTHRITIS INITIATIVE
C. Kwoh y, M.J. Hannon z, T. Fujii x, Z. Wang z, D.J. Hunter k,
A. Guermazi{, F. Roemer#, F. Eckstein yy, J. Grago zz, R. Boudreau x. y The
Univ. of Arizona Arthritis Ctr., Tucson, AZ, USA; zUniv. of Pittsburgh,
Pittsburgh, PA, USA; xUniv. of Pittsburgh Graduate Sch. of Publ. Hlth.,
Pittsburgh, PA, USA; kUniv. of Sydney, Sydney, Australia; {Boston Univ.
Sch. of Med., Boston, MA, USA; #Boston Univ. Sch. of Med.; Dept. of
Radiology, Klinikum Augsburg, Boston, MA, USA; yy Inst. of Anatomy,
Paracelsus Univ., Salzburg, Austria; zz The Univ. of Pittsburgh, Pittsburgh,
PA, USA
Purpose: A history of knee injury or knee surgery has long been known
as an important risk factor for the development of knee osteoarthritis
(OA). Less is known, however, of the time course from knee injury or
knee surgery to the development of radiographic OA (ROA). We utilized
data from the Osteoarthritis Initiative (OAI) to examine the association
of incident knee injury or knee surgery after the baseline visit, with the
development of incident ROA (i.e. deﬁned by the presence of deﬁnite
osteophytes).
Methods: The OAI participants in this nested case-control study had risk
factors for OA, but did not have deﬁnite ROA as yet in the target knee (i.e.,
a baseline Kellgren and Lawrence grade (KLG) of 0 or 1). Participantswere
assessed by PA ﬁxed-ﬂexion knee radiographs using the OAI protocol.
Data was collected on self-report of a history of knee injury or knee
surgery at baseline (BL) and at each subsequent OAI visit. Case kneeswere
those that developed deﬁnite ROA (i.e., KLG2) on knee radiographs at
the 12M through 48M annual visits. The case knees were matched 1:1 to
control knees that did not develop ROA through 48 months by age
(5years), sex, and baseline KLG in the target knee and the contralateral
knee (e.g., KL 0/0, 0/1, 1/1, 0/2, or 1/2). The OAI visit when deﬁnite ROA
was evident was designated as P0. Incident knee injury or knee surgery
was based on new reports of knee injury or knee surgery after baseline
(BL) through the P0 visit. Conditional Logistic Regression was used to
estimate the odds ratios (OR) of subsequent development of ROA for both
incident knee injury or incident knee surgery. Models were controlled for
baseline BMI and history of hand OA as well as the correlation of bilateral
knees within an individual, as appropriate.
Results: There were a total of 355 knees that developed ROA (67%
female) that were matched to 355 controls with a mean age of 60 (SD
8.6) in cases and 60 (8.4) in controls. The majority of cases and con-
trols were overweight, with a BMI of 28.9 (4.5) and 27.7 (4.4)
respectively. As summarized in Table 1, a history of knee injury at
baseline, but not a history of knee surgery at baseline was a signiﬁcant
risk factor for the development of incident ROA (aORs (95% CI) of 1.55
(1.06 to 2.26) and 0.72 (0.34 to 1.56), respectively). Reports of incident
knee injury or incident knee surgery between baseline and P0 were
both associated with an increased risk of incident ROA (aORs (95% CI) of
7.23 (3.55 to 14.73) and 13.92 (4.25 to 45.57), respectively). The risk was
highest following incident knee injury, also incident knee surgery, in
the year prior to the development of incident ROA (aORs (95% CI) of 7.66
(3.14 to 18.69) and 34.81 (5.20 to 233.07), respectively).
Conclusions: To our knowledge, this is the ﬁrst report of an increased
risk of incident ROA that is associated with incident knee injury or knee
surgery. The ﬁndings were obtained in a cohort of individuals that
already had other risk factors for the development of ROA. These results
indicate a potential target population for pharmacologic interventions
or secondary prevention to prevent the development of ROA in at-risk
populations.Table 1
N¼ 355 matched pairs Control Case aOR (95%) CI
Any knee injury at baseline 63 (18%) 89 (25%) 1.55 (1.06–2.26)
Any knee surgery at baseline 22 (6%) 17 (5%) 0.72 (0.34–1.56)
Incident knee injury (BL to P0) 14 (4%) 71 (20%) 7.23 (3.55–14.73)
Incident knee surgery (BL to P0) 3 (1%) 39 (11%) 13.92 (4.25–45.57)
Incident knee injury
(12M prior to P0)
9 (3%) 51 (14%) 7.66 (3.14–18.69)
Incident knee surgery
(12M prior to P0)
1 (0.3%) 32 (9%) 34.81 (5.20–233.07)
